Figure 1.
Anti‐MMP9 antibody improves animal survival benefits of nab‐paclitaxel/gemcitabine. Animal survival study in the peritoneal dissemination model after injecting 0.75 × 106 AsPC‐1 cells (A) or 0.65 × 106 AsPC‐1 cells (B). Two weeks after tumour cell injection in NOD/SCID mice, treatment was started with nab‐paclitaxel, gemcitabine and anti‐MMP9 antibody for 2 wk or 6 wk as specified. The curve represents the animal survival time from the beginning of therapy. Statistical group differences in survival time were calculated using logrank testing